|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.92 USD | +2.86% |
|
+0.05% | +0.21% |
| 12/02 | Biogen Inc. Announces Board Changes | CI |
| 11/02 | RBC Raises Price Target on Exelixis to $46 From $45, Keeps Sector Perform Rating | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 143.5Cr | 161.11Cr | 183.02Cr | 216.87Cr | 232.01Cr | |||||
Total Revenues | 143.5Cr | 161.11Cr | 183.02Cr | 216.87Cr | 232.01Cr | |||||
Cost of Goods Sold, Total | 5.29Cr | 5.79Cr | 7.25Cr | 7.62Cr | 8.37Cr | |||||
Gross Profit | 138.21Cr | 155.32Cr | 175.77Cr | 209.25Cr | 223.64Cr | |||||
Selling General & Admin Expenses, Total | 40Cr | 46Cr | 54Cr | 49Cr | 52Cr | |||||
R&D Expenses | 69Cr | 89Cr | 104.41Cr | 91Cr | 83Cr | |||||
Other Operating Expenses, Total | 109.54Cr | 135.17Cr | 158.68Cr | 140.25Cr | 134.37Cr | |||||
Operating Income | 29Cr | 20Cr | 17Cr | 69Cr | 89Cr | |||||
Interest Expense, Total | - | - | - | - | - | |||||
Interest And Investment Income | 76.72L | 3.31Cr | 8.65Cr | 7.72Cr | 6.92Cr | |||||
Net Interest Expenses | 76.72L | 3.31Cr | 8.65Cr | 7.72Cr | 6.92Cr | |||||
Currency Exchange Gains (Loss) | 8L | 12L | - | - | - | |||||
Other Non Operating Income (Expenses) | -10L | -13.97L | 93T | -1L | -2L | |||||
EBT, Excl. Unusual Items | 29Cr | 23Cr | 26Cr | 77Cr | 96Cr | |||||
Restructuring Charges | - | - | - | -3.37Cr | -2.05Cr | |||||
Gain (Loss) On Sale Of Investments | - | - | - | - | - | |||||
Asset Writedown | - | - | - | -5.17Cr | - | |||||
Other Unusual Items | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | 29Cr | 23Cr | 26Cr | 68Cr | 94Cr | |||||
Income Tax Expense | 6.31Cr | 5.21Cr | 4.98Cr | 16Cr | 16Cr | |||||
Earnings From Continuing Operations | 23Cr | 18Cr | 21Cr | 52Cr | 78Cr | |||||
Net Income to Company | 23Cr | 18Cr | 21Cr | 52Cr | 78Cr | |||||
Net Income - (IS) | 23Cr | 18Cr | 21Cr | 52Cr | 78Cr | |||||
Preferred Dividend and Other Adjustments | - | - | - | - | - | |||||
Net Income to Common Incl Extra Items | 23Cr | 18Cr | 21Cr | 52Cr | 78Cr | |||||
Net Income to Common Excl. Extra Items | 23Cr | 18Cr | 21Cr | 52Cr | 78Cr | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.73 | 0.57 | 0.65 | 1.8 | 2.88 | |||||
Basic EPS - Continuing Operations | 0.73 | 0.57 | 0.65 | 1.8 | 2.88 | |||||
Basic Weighted Average Shares Outstanding | 31Cr | 32Cr | 32Cr | 29Cr | 27Cr | |||||
Net EPS - Diluted | 0.72 | 0.56 | 0.65 | 1.76 | 2.78 | |||||
Diluted EPS - Continuing Operations | 0.72 | 0.56 | 0.65 | 1.76 | 2.78 | |||||
Diluted Weighted Average Shares Outstanding | 32Cr | 32Cr | 32Cr | 30Cr | 28Cr | |||||
Normalized Basic EPS | 0.58 | 0.46 | 0.51 | 1.65 | 2.21 | |||||
Normalized Diluted EPS | 0.57 | 0.45 | 0.5 | 1.62 | 2.13 | |||||
American Depositary Receipts Ratio (ADR) | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | |||||
Supplemental Items | ||||||||||
EBITDA | 30Cr | 22Cr | 20Cr | 72Cr | 92Cr | |||||
EBITA | 29Cr | 20Cr | 17Cr | 69Cr | 89Cr | |||||
EBIT | 29Cr | 20Cr | 17Cr | 69Cr | 89Cr | |||||
EBITDAR | 31Cr | 24Cr | 23Cr | 76Cr | 95Cr | |||||
Total Revenues (As Reported) | 143.5Cr | 161.11Cr | 183.02Cr | 216.87Cr | 232.01Cr | |||||
Effective Tax Rate - (Ratio) | 21.45 | 22.22 | 19.32 | 23.53 | 16.85 | |||||
Current Domestic Taxes | 1.66Cr | 11Cr | 18Cr | 22Cr | 3.24Cr | |||||
Total Current Taxes | 1.66Cr | 11Cr | 18Cr | 22Cr | 3.24Cr | |||||
Deferred Domestic Taxes | 4.65Cr | -6.04Cr | -13Cr | -5.95Cr | 13Cr | |||||
Total Deferred Taxes | 4.65Cr | -6.04Cr | -13Cr | -5.95Cr | 13Cr | |||||
Normalized Net Income | 18Cr | 15Cr | 16Cr | 48Cr | 60Cr | |||||
Interest on Long-Term Debt | - | - | - | - | - | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 3.18Cr | 4.16Cr | 4Cr | 4.35Cr | 5.17Cr | |||||
Selling and Marketing Expenses | 3.18Cr | 4.16Cr | 4Cr | 4.35Cr | 5.17Cr | |||||
Research And Development Expense From Footnotes | 69Cr | 89Cr | 104.41Cr | 91Cr | 83Cr | |||||
Net Rental Expense, Total | 80.17L | 2.14Cr | 3.6Cr | 3.67Cr | 3.19Cr | |||||
Imputed Operating Lease Interest Expense | - | - | - | - | - | |||||
Imputed Operating Lease Depreciation | - | - | - | - | - | |||||
Stock-Based Comp., R&D Exp. (Total) | 4.67Cr | 4.54Cr | 3.43Cr | 3.07Cr | 4.08Cr | |||||
Stock-Based Comp., SG&A Exp. (Total) | 7.32Cr | 6.22Cr | 7.2Cr | 6.32Cr | 7.22Cr | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||||
Total Stock-Based Compensation | 12Cr | 11Cr | 11Cr | 9.38Cr | 11Cr |
- Stock Market
- Equities
- EXEL Stock
- Financials Exelixis, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















